Program
Dimethyl Fumarate
Also written as “dimethyl fumarate”, “BG00012” and “FP187”.
Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis · Psoriasis · Multiple Sclerosis, Chronic Progressive · Arthritis, Rheumatoid, led by 3 companies.
Drug pageDimethyl Fumarate: every studyAll 59 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogenits history only | 331 open or running | phase 4since May 9, 2013 | Sep 9, 2005 | Jul 28, 2034phase 3 · NCT07483632 |
| Almirall | 20 open or running | phase 3since Nov 12, 2012 | Nov 12, 2012 | none ahead |
| Forward-Pharmaits history only | 20 open or running | phase 3since Mar 19, 2013 | Sep 24, 2010 | none ahead |
Also a collaborator on its studies: GB Pharma Services & Consulting s.r.l., Almirall Hermal and Harrison Clinical Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Almirall only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 12, 2012First study: phase 3 study in PsoriasisFirst studyNCT01726933 · 839 enrolled · Austria, Germany, Netherlands and more
- Oct 25, 2016Phase 1 study in PsoriasisNCT02955693 · 32 enrolled · United Kingdom
TargetBeta
“Kelch-like ECH-associated protein 1 inhibitor”ChEMBL 37, by rule
Other programs on KEAP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| diroximel fumaraterule | Biogen | phase 3 | 5 |
Studies
All 2 Almirall leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02955693Psoriasis · United Kingdom | 1 | Completed | Oct 2016 | 32 |
| NCT01726933Psoriasis · Austria, Germany, Netherlands and more | 3 | Completed | Oct 2014 | 839 |
How it is read
Names in the registry
- “dimethyl fumarate”, 19 entries
- “BG00012”, 8 entries
- “FP187”, 5 entries
- “Dimethyl Fumarate”, 2 entries
- “Dimethyl fumarate”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, Relapsing-Remitting, 18 studies
- Multiple Sclerosis, 7 studies
- Psoriasis, 4 studies
- Multiple Sclerosis, Chronic Progressive, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.